Halozyme Therapeutics, Inc.(NASDAQ : HALO)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.16%||69.56||1.0%||$505.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.18%||635.16||2.7%||$472.48m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.31%||203.81||1.9%||$464.56m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-4.21%||4.10||0.7%||$286.61m|
|EXAS||EXACT Sciences Corp.||-4.94%||76.59||18.0%||$140.15m|
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.